Bio-Techne Corp (TECH)
| Market Cap | 13.84B |
| Revenue (ttm) | 1.08B |
| Net Income (ttm) | 225.49M |
| Shares Out | 39.23M |
| EPS (ttm) | 5.49 |
| PE Ratio | 64.26 |
| Forward PE | 36.36 |
| Dividend | $1.28 (0.36%) |
| Ex-Dividend Date | May 13, 2022 |
| Volume | 238,331 |
| Open | 348.69 |
| Previous Close | 345.30 |
| Day's Range | 345.95 - 352.80 |
| 52-Week Range | 318.07 - 543.85 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 520.10 (+47.4%) |
| Earnings Date | Aug 4, 2022 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell sele... [Read more...]
Financial Performance
In 2021, Bio-Techne's revenue was $931.03 million, an increase of 26.04% compared to the previous year's $738.69 million. Earnings were $140.41 million, a decrease of -38.76%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is 520.1, which is an increase of 47.44% from the latest price.
News
BIO-TECHNE TO ACQUIRE NAMOCELL
MINNEAPOLIS and MOUNTAIN VIEW, Mo. , June 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research...
Amy Zhang: this ‘underrated' biotech firm can weather a recession
The iShares Biotechnology ETF (IBB) is still down nearly 25% for the year, but Alger's portfolio manager says there are opportunities within this space that can weather a recession. Zhang's favourite st...
Does Techne (TECH) Have the Potential to Rally 39% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Techne (TECH). While the effectiveness of this highly sought-after metric is questionable, the positive tr...
Bio-Techne Celebrates 40,000 Unique RNAscope™ in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species.
Bio-Techne is extending ACD's leadership in the spatial biology market by passing a milestone of offering 40,000 custom probes in over four hundred species MINNEAPOLIS , May 26, 2022 /PRNewswire/ -- Bio...
GLOBAL STUDY DEMONSTRATES ICE3 AND MAURICE CAPILLARY ISOELECTRIC FOCUSING COMPARABILITY IN THE JOURNAL OF ELECTROPHER...
MINNEAPOLIS , May 25, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of ic...
BIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE
MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare C...
Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test
MINNEAPOLIS and LOS ANGELES, May 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively m...
BIO-TECHNE TO PRESENT AT ANNUAL AMERICAN UROLOGICAL ASSOCIATION CONFERENCE IN NEW ORLEANS
MINNEAPOLIS , May 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American...
Techne (TECH) Beats Q3 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of 7% and 2.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS , May 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 202...
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2022 RESULTS
MINNEAPOLIS, May 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2022. Third Quarter FY2022 Highlights Third quar...
HZNP or TECH: Which Is the Better Value Stock Right Now?
HZNP vs. TECH: Which Stock Is the Better Value Option?
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTHCARE CONFERENCE
MINNEAPOLIS , May 2, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2022 Health...
5 Stock Picks With Bulletproof Profit Margins
Making good stock picks is challenging at any time. But these days, investors must be wary of companies that are vulnerable to higher-for-longer inflation, as well as lingering supply-chain disruptions,...
BIO-TECHNE INCLUDED ON THE FORBES BEST EMPLOYERS FOR DIVERSITY 2022 LIST
MINNEAPOLIS , April 26, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included on the Forbes list of Best Employers for Diversity 2022. This prestigious awa...
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 4, 2022, TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
MINNEAPOLIS , April 13, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. CDT to ...
BIO-TECHNE AND CYGNUS TECHNOLOGIES, PART OF MARAVAI LIFESCIENCES, INTRODUCE NEW SIMPLE PLEX HEK 293 HCP 3G IMMUNOASSAY
MINNEAPOLIS, April 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), announced today the launch of the Simple Plex™ HEK...
BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM
MINNEAPOLIS, March 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTec...
BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS, March 9, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare...
BIO-TECHNE TO PRESENT AT THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE
MINNEAPOLIS, Feb. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Cowen 42nd Ann...
BIO-TECHNE TO PRESENT AT THE CITI 2022 VIRTUAL HEALTHCARE CONFERENCE
MINNEAPOLIS, Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virt...
BIO-TECHNE ANNOUNCES EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR ExoTRU® KIDNEY TRA...
MINNEAPOLIS, Feb. 22, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the E...
VRTX vs. TECH: Which Stock Should Value Investors Buy Now?
VRTX vs. TECH: Which Stock Is the Better Value Option?
BIO-TECHNE ANNOUNCES PUBLICATION OF NEW DATA DEMONSTRATING EXODX PROSTATE TEST CORRELATION WITH POST-PROSTATECTOMY PA...
MINNEAPOLIS, Feb. 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI...